The 4^th Viral Vector Process Development & Manufacturing Summit is a two-day conference that brings together leaders from biopharma, academia, and regulatory authorities to address the most pressing challenges in scalable, safe, and cost-efficient viral vector production for gene and cell therapies. Attendees will engage with expert speakers through technical presentations, interactive sessions, and structured networking to explore strategies for reducing cost of goods, improving process consistency, streamlining upstream and downstream workflows, and aligning with evolving global regulatory standards — all aimed at accelerating the commercial readiness and quality of advanced viral vector manufacturing.

Date: February 25-26, 2026
Location: Hilton Boston Logan Airport Boston, Massachusetts.
https://viral-vector-process-development.com/

SPEAKING ENGAGEMENTS

Title: De-Risking Clinical & Late-Stage AAV with Robust Analytics
Speaker: Philip Wills, Chief Commercial Officer, Catalent
Date & Time: Thursday February 26^th, at 10am local time

ABOUT CATALENT

Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) championing the missions that help people live better and healthier lives. Every product that Catalent helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. Catalent provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives. Catalent tailors end-to-end solutions to meet customers’ needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com.

 

Championing the missions that matter™